Firma Lonza Group Ltd., Autor bei Presse-Blog

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

12. September 2022 Firma Lonza Group Ltd.Firmeninternbayer, cell, clinical, company, gene, lonza, lonzas, market, masters, morphosys, new, risks, securities, statements, with

Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading Mehr

Lonza and Touchlight collaborate on end-to-end mRNA offering

6. September 2022 Firma Lonza Group Ltd.Allgemeincell, clinical, dbdna, doggybone, lonza, lonzas, market, pdna, plasmid, production, rna, touchlight, touchlights, vaccines, with

Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can Mehr

Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin

22. Juli 2022 Firma Lonza Group Ltd.Finanzen / Bilanzencapsule, cell, cer, chf, cocoon, ebitda, esg, financial, lonza, lonzas, market, new, shipments, strong, with

In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook Mehr

Maria Soler Nunez appointed as Head, Group Operations

1. Juli 2022 Firma Lonza Group Ltd.Firmeninternany, board, clinical, company??s, lonza, may, medical, new, prior, release, risks, securities, statements, Trading, with

. Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who Mehr

Grand Opening of Kodiak Sciences‘ Purpose-Built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases

18. Mai 2022 Firma Lonza Group Ltd.Forschung und Entwicklungamd, bioconjugation, biopark, dosing, glaucoma, ksi, lonza, lonzas, market, palo, patients, retinal, vegf, vein, with

. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion Mehr

Lonza Announces Results of the 2022 Annual General Meeting – All Motions Proposed by Board of Directors Accepted

5. Mai 20227. Mai 2022 Firma Lonza Group Ltd.Finanzen / Bilanzenagm, chf, dividend, financial, lonza, lonzas, new, report, risks, securities, shareholders, statements, steinemann, tax, with

Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Mehr

Lonza Publishes Invitation to the 2022 Annual General Meeting and 2021 Annual and Sustainability Reports

24. März 202224. März 2022 Firma Lonza Group Ltd.Finanzen / Bilanzenchf, dividend, embedded, esg, healthineers, heidelberg, INTEGRA, lonza, lonzas, neurimmune, novago, prosiebensat1, siemens, tax, with

. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors Stable dividend of CHF 3.00 per share proposed 2021 Mehr

Christian Seufert appointed as President of Capsules and Health Ingredients Division

23. März 2022 Firma Lonza Group Ltd.Firmeninternamerica, basf, board, capsules, cleaning, covid, dartiguelongue, imd, ingredients, lonza, market, new, solutions, strong, with

. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses He will commence Mehr

Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)

26. Januar 2022 Firma Lonza Group Ltd.Finanzen / Bilanzenapm, bericht, cell, cer, chf, ebitda, exosomen, gamsenried, healthineers, heidelberg, kwk, lonza, lonzas, neurimmune, siemens

Lonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1 CHF 1.7 Milliarden Kern-EBITDA resultieren in einer Marge von 30,8% 2021 erreichten die Investitionsausgaben 24% des Umsatzes und unterstützten den langfristigen Plan durch risikoarme Wachstumsinvestitionen attraktive Mehr

Lonza Delivers Strong 2021 performance with 20% CER Sales Growth

26. Januar 2022 Firma Lonza Group Ltd.Finanzen / Bilanzenapm, cer, chf, dividend, ebitda, exosomes, gamsenried, heidelberg, lonza, lonzas, market, neurimmune, siemens, statements, with

Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments Continuing focus Mehr

Autor: Firma Lonza Group Ltd.